Olanzapine orodispersible tablets occupied all three of the top places in WaveData’s table of the UK generics market’s Biggest Risers for May 2023, according to the latest figures from the market researcher.
UK Olanzapine Prices Rocket Up In May
Pricewatch UK – May 2023
Three presentations of olanzapine orodispersible tablets topped our table of the UK generics market’s Biggest Risers for May 2023.
More from Drug Pricing
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
Walmart has launched an attack on a host of industry-leading generics firms over historical price-fixing allegations, with the US retail giant seeking treble damages from a Pennsylvania district court.
• By
In the wake of Formycon’s recent announcement that US marketing partner Sandoz would be pausing commercialization of the Cimerli rival to Lucentis that it recently took over from Coherus, Sandoz management has offered a few more details on its plans for the ranibizumab biosimilar.
• By
Sandoz CEO Richard Saynor has spoken of his frustration at a lawsuit from J&J seeking to prevent the launch of a private-label ustekinumab biosimilar in the US, which he described as “the desperate actions of an originator trying to protect its market.”
More from Market Intelligence
• By
Dementia treatment memantine saw the steepest rise in its UK trade price in November, according to the latest figures from WaveData.
• By
After a few months of steep UK price rises for apixaban generics, October saw a correction as average prices headed in the opposite direction, the latest figures from WaveData reveal.
• By
Generics of the schizophrenia treatment Latuda generated more than $4bn in savings a year after their 2022 approval, according to an FDA study.